De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Viracta Therapeutics Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Mark Rothera

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris	40.5%
Dienstverband CEO	2.1yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	3.7yrs

Recente managementupdates

Recent updates

Viracta Therapeutics names Mark Rothera as new CEO

Sep 19

Viracta Therapeutics gets European orphan drug designation for lymphoma combo treatment

Sep 07

Viracta Therapeutics GAAP EPS of -$0.28

Aug 09

Viracta Therapeutics files for $200M mixed shelf offering

May 28

Analyse CEO-vergoeding

Hoe is Mark Rothera's beloning veranderd ten opzichte van Viracta Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$45m
Mar 31 2024	n/a	n/a	-US$48m
Dec 31 2023	US$1m	US$590k	-US$51m
Sep 30 2023	n/a	n/a	-US$48m
Jun 30 2023	n/a	n/a	-US$53m
Mar 31 2023	n/a	n/a	-US$51m
Dec 31 2022	US$6m	US$167k	-US$49m

Compensatie versus markt: De totale vergoeding ($USD 1.46M ) Mark } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Mark is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Mark Rothera (61 yo)

2.1yrs

Tenure

US$1,456,596

Compensatie

Mr. Mark Andrew Rothera serves as Chief Executive Officer, President & Director of Viracta Therapeutics, Inc. since September 19, 2022. He served as President, Chief Executive Officer and Executive Directo...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Rothera	CEO, President & Director	2.1yrs	US$1.46m	geen gegevens
Darrel Cohen	Chief Medical Officer	1.2yrs	US$1.05m	0% $ 0
Susan Perrine	Scientific Founder and Consultant	13.8yrs	geen gegevens	geen gegevens
Ronald Berenson	Co-Founder and Consultant	13.8yrs	geen gegevens	geen gegevens
George Hillman	Co-Founder	no data	geen gegevens	geen gegevens
Thalia Papayannopoulou	Co-Founder	no data	geen gegevens	geen gegevens
Robert Williams	Co-Founder	no data	geen gegevens	geen gegevens
Douglas Faller	Scientific Founder & Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michael Faerm	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Ayman El-Guindy	Chief Scientific Officer	3.3yrs	geen gegevens	geen gegevens
Cheryl Madsen	Senior Vice President of Regulatory Affairs	3.6yrs	geen gegevens	geen gegevens
Patric Nelson	Senior Vice President of Business Development & Corporate Strategy	3.3yrs	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VIRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Rothera	CEO, President & Director	2.1yrs	US$1.46m	geen gegevens
Douglas Faller	Scientific Founder & Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Ivor Royston	Director	3.7yrs	US$90.76k	2.11% $ 191.5k
Thomas Darcy	Independent Director	3.7yrs	US$113.26k	0% $ 0
Ronald Levy	Member of Scientific Advisory Board	6.1yrs	geen gegevens	geen gegevens
Carl June	Member of Scientific Advisory Board	6.1yrs	geen gegevens	geen gegevens
Barry Simon	Independent Director	3.6yrs	US$110.76k	0% $ 0
Roger Pomerantz	Independent Chairman of the Board	3.7yrs	US$210.27k	0.30% $ 27.0k
Lawrence Young	Member of Scientific Advisory Board	6.1yrs	geen gegevens	geen gegevens
Robert Baiocchi	Member of Scientific Advisory Board	6.1yrs	geen gegevens	geen gegevens
Pierluigi Porcu	Member of Scientific Advisory Board	6.1yrs	geen gegevens	geen gegevens
Stephen Rubino	Independent Director	3.6yrs	US$108.26k	0% $ 0

3.7yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VIRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Viracta Therapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

High number of new directors

High number of new directors

Recent updates

New major risk - Market cap size

New major risk - Financial position

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

New major risk - Revenue and earnings growth

Viracta Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing under Nasdaq Listing Rule 5450(a)(1)

Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

New major risk - Revenue and earnings growth

Price target decreased by 20% to US$7.00

Viracta Therapeutics, Inc. Provides Clinical Update

Viracta Therapeutics Announces Interim Data from Phase 1B/2 Clinical Trial of Nana-Val in Patients with Epstein-Barr Virus-Positive Solid Tumors That Show Confirms Tumor Responses At Higher Dose Levels

Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC

Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

Price target decreased by 36% to US$9.40

Price target decreased by 9.1% to US$14.00

Viracta Therapeutics’ Pivotal Naval-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Viracta Therapeutics, Inc. Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

Viracta Therapeutics, Inc. Announces Preliminary Dose-Ranging Data from the Phase 1B/2 Trial of Nana-Val in Patients

Price target decreased to US$15.00

High number of new directors

High number of new directors

High number of new directors

Viracta Therapeutics, Inc. Announces CEO Changes

Viracta Therapeutics names Mark Rothera as new CEO

Viracta Therapeutics gets European orphan drug designation for lymphoma combo treatment

CEO, President & Director exercised options and sold US$54k worth of stock

Viracta Therapeutics, Inc. Announces Resignation of Michael Huang as Director

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

Viracta Therapeutics GAAP EPS of -$0.28

Viracta Therapeutics, Inc.(NasdaqGS:VIRX) dropped from Russell 2500 Value Index

Viracta Therapeutics, Inc. Provides an Update on the Phase 1b/2 Trial of Nana-Val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Price target decreased to US$21.40

Less than half of directors are independent

Viracta Therapeutics, Inc. Announces That Gur Roshwalb Will Not Stand for Re-Election At the Company’s 2022 Annual Meeting of Stockholders

Price target increased to US$31.50

Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors

Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021

CEO, President & Director exercised options and sold US$133k worth of stock

Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Viracta Therapeutics, Inc. Announces the Initiation of Naval-1, A Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma

Viracta Therapeutics files for $200M mixed shelf offering

Viracta Therapeutics, Inc. Announces Executive Changes

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd